This study showed a significant improvement in all symptoms and QoL factors evaluated. More than 90% of participants in this study reported product satisfaction and would use xylometazoline hydrochloride 0.1% again. As participants were recruited at an early stage of the common cold and started treatment by the peak symptom stage, changes in symptom severity during this study may be attributed to xylometazoline hydrochloride 0.1% treatment. Given the well-known natural history of the common cold, 12 and that xylometazoline hydrochloride 0.1% efficiently reduces nasal congestion, 14 these data suggest that nasal congestion relief may positively impact participants’ QoL.